Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.
about
Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trialsTreatment of relapsed and refractory multiple myelomaTargeted treatments for multiple myeloma: specific role of carfilzomibA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaClinical use of proteasome inhibitors in the treatment of multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsA phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.Nucleolar stress with and without p53.Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors.Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.Carfilzomib boosted combination therapy for relapsed multiple myelomaSmoldering multiple myeloma: present position and potential promises.International Myeloma Working Group recommendations for global myeloma care.Future agents and treatment directions in multiple myeloma.New drugs in multiple myeloma - role of carfilzomib and pomalidomide.Salvage therapy of multiple myeloma: the new generation drugs.An analysis of the safety profile of proteasome inhibitors for treating various cancers.Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation.Current treatment landscape for relapsed and/or refractory multiple myeloma.Defining and treating high-risk multiple myeloma.A practical review on carfilzomib in multiple myeloma.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.Management of high-risk Myeloma: an evidence-based review of treatment strategies.High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p).Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion.Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal.
P2860
Q26741620-8E4BDC19-45FF-4138-B7C7-8FB4C01A3164Q26749180-1E4E68BE-EB66-45FB-9C42-9C408DFCDAF1Q26996524-E5A1460A-468B-4CE0-BCE8-8BA5E9E77EFBQ28067148-81925FDB-1053-4C68-ADC9-B157BEE6CDFEQ28080999-14F49F3A-CDBA-43ED-89B8-49D145143B5AQ28082910-7A40731E-C85B-4F3A-805E-3A77B8BF7EDCQ28084683-9E72B3F0-427D-44B3-92E1-5DCCBBFA1ECBQ33416105-201C257E-B7BA-490B-97C7-970FC7E53250Q33785935-50B62A81-288F-4D2E-92B9-3CB77FDD0781Q34183329-74C42F43-A713-42C4-B439-D52AA636B84BQ35509621-E23BC33F-6090-4A13-95B6-009A81A924C4Q36115674-DA26920C-BEAC-42C2-8E1D-4BE827207F97Q37037265-B95699C8-2366-47DC-A841-DA2EA87F8B15Q37228327-D3662E8E-CD06-4954-8FBD-8EDF3DA8E07CQ37652953-45595C56-687C-4818-A943-7E5CA6D082D8Q38151230-5A00878A-5D6B-4D0B-8C0B-A3140BFD62C7Q38157532-B9C36AC5-1125-4505-9B15-D78EEF7D198BQ38172300-50B65D7C-2F38-40FD-BD93-121FD58770F8Q38216018-9EAB82A2-B601-4824-8733-F716D300903EQ38223433-292FEBD6-EAD9-4D36-8216-8D3225DA0BD6Q38227506-D5E8B6A8-F294-46E9-860D-9267239A5BD4Q38255333-54701E76-D9DE-433D-AC47-17005193D51BQ38268782-CC854B74-1A72-4104-AD77-4347000257D2Q38271032-E8682B51-3993-45FC-9EDE-B1A65844C7B7Q38564926-EECF7BED-C4BC-4830-A71B-B0E68C673140Q38740271-66F0017F-7AD0-4765-A3F6-4E1F9CB97D34Q38757067-156B44D9-17EF-4670-9806-6BECC726D2BAQ38874675-D11DA366-8FB7-481B-B089-8FFEAEB1F44EQ38979403-1223A046-C8DD-4FF2-8E36-84F53F5DB0D1Q38989789-7FA28767-D0E7-447E-B659-A83B4589B529Q39024879-24596E42-2F63-4802-9EDE-8C265D28C8DBQ40111192-F02FAA50-6547-4350-807E-30EFADDC9FE6Q40928974-C9AE870D-E5E4-4395-A632-34853E89EDCEQ41963512-4C3AE518-8BDF-4F7F-9256-B02FB2A37B49Q42365345-ABB38C42-771D-49B2-9889-A03FCF1AE670Q47115348-F8171C31-6E8D-447D-A7A0-7B0C3889907BQ47707509-3680608C-0EED-4CB5-B665-B4AD80EC7830Q54458683-98B0693E-F4AA-482F-9950-A50C90EC70D2
P2860
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment outcomes in patients ...... ib in the PX-171-003-A1 study.
@en
Treatment outcomes in patients ...... ib in the PX-171-003-A1 study.
@nl
type
label
Treatment outcomes in patients ...... ib in the PX-171-003-A1 study.
@en
Treatment outcomes in patients ...... ib in the PX-171-003-A1 study.
@nl
prefLabel
Treatment outcomes in patients ...... ib in the PX-171-003-A1 study.
@en
Treatment outcomes in patients ...... ib in the PX-171-003-A1 study.
@nl
P2093
P2860
P356
P1433
P1476
Treatment outcomes in patients ...... ib in the PX-171-003-A1 study.
@en
P2093
A Chanan-Khan
A J Jakubowiak
A K Stewart
B L Harrison
D S Siegel
E Stadtmauer
P2860
P2888
P304
P356
10.1038/LEU.2013.152
P577
2013-05-14T00:00:00Z